Where is the ID code?
This site is intended for patients who are 18 years or older and a legal resident of the U.S. or Puerto Rico.
Activate Your True Blue Savings Card
Terms & Conditions
True Blue Savings program benefits
With the Migitare True Blue Savings card, eligible patients can receive their first fill for as little as $0 up to a maximum value of $65. For refills, eligible patients can save on their out-of-pocket costs and pay as little as $5 per refill for their Mitigare® (colchicine) 0.6 mg Capsules (or its Authorized Generic Colchicine 0.6 mg capsules) prescription up to a maximum value of $50 per 30-day supply (up to a maximum of 60 capsules). Dispenses for 60 day supply (up to a maximum of 120 capsules) and 90 day supply (up to a maximum of 180 capsules) are permissible within the terms of the program, up to a total of a 12 month supply.
Savings card activation
Your card must be activated to use it. For patients with a True Blue Savings card (oval shaped) from their doctor, please active your card online at Mitigare.com, or by calling 1-877-259-6893. If you downloaded and printed your savings card online at Mitigare.com, it will automatically be activated and ready for use at the pharmacy. Limit 1 card per patient.
This card is not transferable. You are not eligible if you are enrolled in any state or federally funded healthcare program, including, but not limited to, Medicare, Medicare Part D, Medicaid (including Medicaid managed care), Medigap, VA, FEHB, DOD, TRICARE, or a state pharmacy assistance program. In addition, you must be 18 years or older and a legal resident of the U.S. or Puerto Rico. Offer void in MA or where prohibited by law, taxed, or restricted. Other conditions may apply.
How to use your True Blue Savings card
To receive the benefits of this program, you must present the savings card to your pharmacist along with a valid Mitigare® (or its Authorized Generic Colchicine 0.6 mg capsules) prescription. This program is not health insurance. Hikma Pharmaceuticals USA Inc. has the right to rescind, revoke, or amend this program without notice. Your participation in this program confirms that this offer is consistent with your insurance coverage, if any, and that you will report the value received if required by your insurance provider. When you use this card, you are certifying that you understand and will comply with the terms and conditions set forth herein. For questions, please call 1-877-259-6893, 8 am-7 pm ET, Monday-Friday.
If your pharmacy is unable to process this card, please mail a copy of your pharmacy receipt indicating Mitigare® (or its Authorized Generic Colchicine 0.6 mg capsules) and the amount paid to: Mitigare® Savings Program, PO Box 42638, Cincinnati, OH 45242. Please allow up to 8 weeks for processing.
Mitigare® Important Safety Information
- Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
- Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
- Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
- Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
- Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
- Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
- The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.
Indication
Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare® for acute treatment of gout flares during prophylaxis has not been studied. Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.
For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch or call 1-800-FDA-1088.
Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228
© 2021 Hikma Pharmaceuticals USA Inc. All Rights Reserved.